Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Finbarr P M O'Harte

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Biological Chemistry|November 9, 2013
Effects of short-term chemical ablation of glucagon signalling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in miceZara J Franklin, Finbarr P M O'Harte, Nigel Irwin
Molecular and Cellular Endocrinology|January 7, 2020
Chronic apelin analogue administration is more effective than established incretin therapies for alleviating metabolic dysfunction in diabetic db/db miceFinbarr P M O'Harte, Vadivel Parthsarathy, Peter R Flatt
Peptides|September 15, 2023
An update on galanin and spexin and their potential for the treatment of type 2 diabetes and related metabolic disordersDaniel M Gallagher, Finbarr P M O'Harte, Nigel Irwin
European Journal of Pharmacology|April 9, 2013
desHis¹Glu⁹-glucagon-[mPEG] and desHis¹Glu⁹(Lys³⁰PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activityNigel Irwin, Zara J Franklin, Finbarr P M O'Harte
Peptides|December 3, 2021
Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A reviewJ Michael Conlon, Finbarr P M O'Harte, Peter R Flatt
Neuropeptides|November 11, 2003
Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?Victor A Gault, Finbarr P M O'Harte, Peter R Flatt
Biochemical and Biophysical Research Communications|August 7, 2003
Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetesVictor A Gault, Peter R Flatt, Finbarr P M O'Harte
Diabetes, Obesity & Metabolism|July 22, 2017
Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic miceVadivel Parthsarathy, Christopher Hogg, Peter R Flatt, et al.
Biochimica Et Biophysica Acta|April 16, 2013
(pGlu-Gln)-CCK-8[mPEG]: a novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetesNigel Irwin, Pamela Frizelle, Finbarr P M O'Harte, et al.
The Journal of Endocrinology|October 12, 2012
Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal miceNigel Irwin, Pamela Frizelle, Finbarr P M O'Harte, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Biological Chemistry|November 9, 2013
Effects of short-term chemical ablation of glucagon signalling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in miceZara J Franklin, Finbarr P M O'Harte, Nigel Irwin
Molecular and Cellular Endocrinology|January 7, 2020
Chronic apelin analogue administration is more effective than established incretin therapies for alleviating metabolic dysfunction in diabetic db/db miceFinbarr P M O'Harte, Vadivel Parthsarathy, Peter R Flatt
Peptides|September 15, 2023
An update on galanin and spexin and their potential for the treatment of type 2 diabetes and related metabolic disordersDaniel M Gallagher, Finbarr P M O'Harte, Nigel Irwin
European Journal of Pharmacology|April 9, 2013
desHis¹Glu⁹-glucagon-[mPEG] and desHis¹Glu⁹(Lys³⁰PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activityNigel Irwin, Zara J Franklin, Finbarr P M O'Harte
Peptides|December 3, 2021
Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A reviewJ Michael Conlon, Finbarr P M O'Harte, Peter R Flatt
Neuropeptides|November 11, 2003
Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?Victor A Gault, Finbarr P M O'Harte, Peter R Flatt
Biochemical and Biophysical Research Communications|August 7, 2003
Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetesVictor A Gault, Peter R Flatt, Finbarr P M O'Harte
Diabetes, Obesity & Metabolism|July 22, 2017
Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic miceVadivel Parthsarathy, Christopher Hogg, Peter R Flatt, et al.
Biochimica Et Biophysica Acta|April 16, 2013
(pGlu-Gln)-CCK-8[mPEG]: a novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetesNigel Irwin, Pamela Frizelle, Finbarr P M O'Harte, et al.
The Journal of Endocrinology|October 12, 2012
Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal miceNigel Irwin, Pamela Frizelle, Finbarr P M O'Harte, et al.
Pageof 7